Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock

BY Benzinga
— 7:12 AM ET 05/19/2022

Ark Investment Management, led by Tesla Inc. NASDAQ:TSLA bull Cathie Wood, on Wednesday scooped up 4.75 million shares estimated to be worth $11.5 million in Ginkgo Bioworks Holdings Inc NYSE:DNA on the day the synthetic biology company slumped lower.

Ginkgo Bioworks closed 11.3% lower at $2.43 on Wednesday and is down 72% year-to-date.

Ark Invest has been piling up shares in the Boston, Massachusetts-based biotech company since it began trading on the New York Stock Exchange in September. Ginkgo Bioworks specializes in using genetic engineering to produce bacteria with industrial applications.

The asset management firm owns the stock via the Ark Genomic Revolution ETF BATS:ARKG and the Ark Innovation ETF NYSE:ARKK.

The two ETFs together held 73.3 million shares -- worth $200.8 million -- in Ginkgo Bioworks ahead of Wednesday's trade. 

See Also: Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'

Besides Ark Invest, Microsoft Corp NASDAQ:MSFT cofounder Bill Gates is the other known high-profile investor in the biotech company.

Ginkgo stock was hit hard last year after two back-to-back short-seller reports alleged that the company was a "colossal scam" and "a scheme."

Photo courtesy: Ginkgo

More MSFT News

  • US STOCKS-Futures signal more selling on Wall Street as growth fears mount
    Reuters - 6:51 AM ET 05/19/2022
  • How You Can Score A Free 3-Month Xbox PC Game Pass
    Benzinga - 4:16 AM ET 05/19/2022
  • A Decade From Facebook's IPO: Here's How Much $1,000 Invested In 2012 Is Worth Today Vs. Big Tech Peers
    Benzinga - 11:17 PM ET 05/18/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close